This inventor holds 3 USPTO granted patents and 3 published patent applications. Top assignee: University of Pittsburgh. Active years: 2020-2025.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
Company Filing History:
Years Active: 2020-2025
Title: Innovations by Carlos Jaime Camacho
Introduction
Carlos Jaime Camacho is an accomplished inventor based in Pittsburgh, PA (US). He has made significant contributions to the field of neuroscience through his innovative research and development of small molecule compounds. With a total of 3 patents, his work focuses on addressing various neurological disorders and inflammation pathways.
Latest Patents
One of his latest patents is titled "Neuroprotective disruption of Kv2.1/syntaxin interaction by small molecules." This patent discloses small molecule compounds capable of disrupting the binding between Kv2.1 and syntaxin. These compounds are particularly useful for treating a variety of neurological disorders, diseases, and injuries. Another notable patent is "Small molecules that specifically inhibit TNF-induced NF-KB inflammation pathway." This patent provides small molecules that specifically inhibit the TNF-induced nuclear factor kB (NF-kB) inflammation pathway. It also outlines methods for screening compounds to identify molecules that inhibit this pathway, as well as methods for preventing the formation of the mature TNFR1 complex.
Career Highlights
Carlos works at the University of Pittsburgh, where he continues to advance his research in the field of neuroscience. His innovative work has garnered attention and recognition within the scientific community.
Collaborations
He collaborates with notable colleagues, including Robin E C Lee and Adam C Straub, to further enhance the impact of his research.
Conclusion
Carlos Jaime Camacho's contributions to neuroscience through his patents and research at the University of Pittsburgh highlight his commitment to innovation in addressing neurological disorders. His work continues to pave the way for new therapeutic approaches.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
